13F Data
13F filer · CIK 1720702

Ponoi Management, LLC

San Francisco, CA · filing since Q4 2020 · last filing Nov 14, 2022
Reported value
$73.2M
+$9.9M vs prior
Positions
4
New / sold out
0 / 0
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $0
Top-10 weight
100.0%

Biggest buys vs Q2 2022

No new or increased positions this quarter.

Biggest sells vs Q2 2022

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2020: $174.8MQ1 2021: $170.0MQ2 2021: $180.0MQ3 2021: $112.6MQ4 2021: $108.5MQ1 2022: $77.0MQ2 2022: $63.3MQ3 2022: $73.2M
Q4 2020Q3 2022

Holdings · Q3 2022

#SecuritySharesValueWeight
1RAPT Therapeutics IncCOM1,599,417$38.5M52.54%
2NGM Biopharmaceuticals IncCOM1,298,908$17.0M23.20%
3Revolution Medicines IncCOM685,011$13.5M18.44%
4Nurix Therapeutics IncCOM327,123$4.3M5.82%